Pallas Capital Advisors LLC Acquires 1,225 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Pallas Capital Advisors LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 19.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 7,673 shares of the company’s stock after purchasing an additional 1,225 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Neurocrine Biosciences were worth $1,047,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences during the second quarter worth about $28,000. Blue Trust Inc. increased its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares in the last quarter. Plato Investment Management Ltd raised its stake in shares of Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after acquiring an additional 130 shares during the last quarter. Truvestments Capital LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $63,000. Finally, True Wealth Design LLC boosted its holdings in shares of Neurocrine Biosciences by 11,740.0% in the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after acquiring an additional 587 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. The trade was a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,694 shares of company stock worth $479,230 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NBIX shares. HC Wainwright reaffirmed a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. UBS Group upped their price target on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Wedbush restated an “outperform” rating and issued a $148.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $164.81.

Neurocrine Biosciences Trading Up 1.5 %

NASDAQ:NBIX opened at $143.03 on Tuesday. The firm has a market capitalization of $14.48 billion, a price-to-earnings ratio of 38.35 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The business’s 50-day moving average price is $130.43 and its two-hundred day moving average price is $131.01.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.